BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425-2432. [PMID: 17711550 DOI: 10.1111/j.1600-6143.2007.01941.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
2 Jalandhara N, Arora R, Batuman V. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update. Clin Pharmacol Ther 2011;89:920-3. [DOI: 10.1038/clpt.2010.346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
3 Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. J Magn Reson Imaging 2009;29:887-94. [PMID: 19306428 DOI: 10.1002/jmri.21708] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
4 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
5 Morcos SK, Dawson P. Comments on the case report reported by Elmholdt et al. NDT Plus 2010;3:501-2. [PMID: 25984068 DOI: 10.1093/ndtplus/sfq097] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
7 Alhadad A, Sterner G, Svensson Å, Alhadad H, Leander P. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scandinavian Journal of Urology and Nephrology 2012;46:48-53. [DOI: 10.3109/00365599.2011.621142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Todd DJ, Kay J. Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Curr Rheumatol Rep 2008;10:195-204. [DOI: 10.1007/s11926-008-0033-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
10 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 8.5] [Reference Citation Analysis]
11 Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54-58. [PMID: 21572794 DOI: 10.4103/0019-5154.77554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-8. [PMID: 18356456 DOI: 10.2214/AJR.07.2822] [Cited by in Crossref: 112] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
13 Sieber MA, Steger-hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009;30:1268-76. [DOI: 10.1002/jmri.21971] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 6.1] [Reference Citation Analysis]
14 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
15 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
16 Kartamihardja AA, Nakajima T, Kameo S, Koyama H, Tsushima Y. Impact of Impaired Renal Function on Gadolinium Retention After Administration of Gadolinium-Based Contrast Agents in a Mouse Model. Invest Radiol 2016;51:655-60. [PMID: 27299580 DOI: 10.1097/RLI.0000000000000295] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 9.8] [Reference Citation Analysis]
17 Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Fisher GJ, Johnson KJ, Swartz R, Varani J. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 2009;44:433-9. [PMID: 19561517 DOI: 10.1097/RLI.0b013e3181a4d7e9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
18 Sieber MA, Lengsfeld P, Walter J, Schirmer H, Frenzel T, Siegmund F, Weinmann HJ, Pietsch H. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 2008;27:955-62. [PMID: 18425843 DOI: 10.1002/jmri.21368] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
19 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
20 Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73. [PMID: 18545998 DOI: 10.1007/s00330-008-0977-y] [Cited by in Crossref: 153] [Cited by in F6Publishing: 127] [Article Influence: 11.8] [Reference Citation Analysis]
21 Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009;24:856-63. [PMID: 18952698 DOI: 10.1093/ndt/gfn593] [Cited by in Crossref: 108] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
22 Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol 2008;23:2121-9. [PMID: 18543004 DOI: 10.1007/s00467-008-0862-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
23 Brambilla S, Valaperta S, Graziani G, Montanelli A. Gadolinium and lanthanum: A iatrogenic transmetallation? Clinical Biochemistry 2008;41:1029-33. [DOI: 10.1016/j.clinbiochem.2008.05.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
24 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
25 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
26 Khurana A, Greene JF Jr, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-24. [PMID: 18538448 DOI: 10.1016/j.jaad.2008.04.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
27 Thakral C, Abraham JL. Gadolinium-Induced Nephrogenic Systemic Fibrosis Is Associated with Insoluble Gd Deposits in Tissues: In Vivo Transmetallation Confirmed by Microanalysis. Journal of Cutaneous Pathology 2009;36:1244-54. [DOI: 10.1111/j.1600-0560.2009.01283.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
28 Boyd AS, Sanyal S, Abraham JL. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? J Am Acad Dermatol 2010;62:337-42. [PMID: 19939504 DOI: 10.1016/j.jaad.2009.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
29 Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180:830-5; discussion 835. [PMID: 18635232 DOI: 10.1016/j.juro.2008.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
30 Bridges MD, St. Amant BS, Mcneil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function. American Journal of Roentgenology 2009;192:1538-43. [DOI: 10.2214/ajr.07.3895] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
31 Penfield JG, Reilly RF. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium-Based Contrast Agents?: GADOLINIUM CHELATE DIFFERENCES AND NSF RISK. Seminars in Dialysis 2008;21:129-34. [DOI: 10.1111/j.1525-139x.2007.00408.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
32 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 5.6] [Reference Citation Analysis]
34 Heinz-Peer G, Neruda A, Watschinger B, Vychytil A, Geusau A, Haumer M, Weber M. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. Eur J Radiol 2010;76:129-34. [PMID: 19619969 DOI: 10.1016/j.ejrad.2009.06.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
35 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
36 Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 2008;13:235-41. [PMID: 18221255 DOI: 10.1111/j.1440-1797.2007.00912.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
37 Lanzman RS, Ljimani A, Pentang G, Zgoura P, Zenginli H, Kröpil P, Heusch P, Schek J, Miese FR, Blondin D. Kidney transplant: functional assessment with diffusion-tensor MR imaging at 3T. Radiology. 2013;266:218-225. [PMID: 23169797 DOI: 10.1148/radiol.12112522] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
38 Weigle JP, Broome DR. Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. Skeletal Radiol 2008;37:457-64. [DOI: 10.1007/s00256-008-0464-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
39 Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010;83:590-5. [PMID: 20413447 DOI: 10.1259/bjr/17689538] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
40 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
41 Provenzale JM. Nephrogenic Systemic Fibrosis: Some Considerations on the Debate Regarding Its Cause. American Journal of Roentgenology 2008;191:1867-9. [DOI: 10.2214/ajr.08.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 van der Molen A. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. Journal of Medical Imaging and Radiation Oncology 2008;52:339-50. [DOI: 10.1111/j.1440-1673.2008.01965.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
43 Rofsky NM. Nephrogenic systemic fibrosis: considerations for the cardiologist. JACC Cardiovasc Imaging 2008;1:457-9. [PMID: 19356467 DOI: 10.1016/j.jcmg.2008.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Adv Chronic Kidney Dis. 2011;18:188-198. [PMID: 21531325 DOI: 10.1053/j.ackd.2011.03.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
45 Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. European Journal of Radiology 2008;66:230-4. [DOI: 10.1016/j.ejrad.2008.02.011] [Cited by in Crossref: 223] [Cited by in F6Publishing: 161] [Article Influence: 17.2] [Reference Citation Analysis]
46 Czeyda-Pommersheim F, Martin DR, Costello JR, Kalb B. Contrast Agents for MR Imaging. Magn Reson Imaging Clin N Am 2017;25:705-11. [PMID: 28964460 DOI: 10.1016/j.mric.2017.06.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
48 Leung N, Shaikh A, Cosio FG, Griffin MD, Textor SC, Gloor JM, Schwab TR, Larson TS, Dean PG, Prieto M, Nyberg SL, Stegall MD, Lee CU, Pittelkow MR. The Outcome of Patients with Nephrogenic Systemic Fibrosis after Successful Kidney Transplantation. American Journal of Transplantation 2010;10:558-62. [DOI: 10.1111/j.1600-6143.2009.02959.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Marckmann P. Nephrogenic systemic fibrosis: epidemiology update: . Current Opinion in Nephrology and Hypertension 2008;17:315-9. [DOI: 10.1097/mnh.0b013e3282f4b605] [Cited by in Crossref: 32] [Article Influence: 2.5] [Reference Citation Analysis]
50 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
51 Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3:968-75. [PMID: 18385397 DOI: 10.2215/CJN.00100108] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
52 Thomsen HS. Nephrogenic Systemic Fibrosis: NEPHROGENIC SYSTEMIC FIBROSIS. Imaging Decisions MRI 2008;11:13-8. [DOI: 10.1111/j.1617-0830.2007.00110.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
53 Roditi G, Maki JH, Oliveira G, Michaely HJ. Renovascular imaging in the NSF Era. J Magn Reson Imaging. 2009;30:1323-1334. [PMID: 19937926 DOI: 10.1002/jmri.21977] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
54 Bardin T, Richette P. Rheumatic manifestations of renal disease. Current Opinion in Rheumatology 2009;21:55-61. [DOI: 10.1097/bor.0b013e32831ca5c5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
55 Brasch RC. Contrast media toxicity in children. Pediatr Radiol 2008;38:281-4. [DOI: 10.1007/s00247-008-0773-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
56 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]